These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37806183)

  • 1. The TGFBI gene and protein expression in topotecan resistant ovarian cancer cell lines.
    Wojtowicz K; Świerczewska M; Nowicki M; Januchowski R
    Adv Med Sci; 2023 Sep; 68(2):379-385. PubMed ID: 37806183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer.
    Wang N; Zhang H; Yao Q; Wang Y; Dai S; Yang X
    J Exp Clin Cancer Res; 2012 Jan; 31(1):6. PubMed ID: 22248469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines.
    Świerczewska M; Klejewski A; Wojtowicz K; Brązert M; Iżycki D; Nowicki M; Zabel M; Januchowski R
    Molecules; 2017 Oct; 22(10):. PubMed ID: 29027969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines.
    Sterzyńska K; Klejewski A; Wojtowicz K; Świerczewska M; Andrzejewska M; Rusek D; Sobkowski M; Kędzia W; Brązert J; Nowicki M; Januchowski R
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance Development.
    Sterzyńska K; Klejewski A; Wojtowicz K; Świerczewska M; Nowacka M; Kaźmierczak D; Andrzejewska M; Rusek D; Brązert M; Brązert J; Nowicki M; Januchowski R
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30583585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperine Targets Different Drug Resistance Mechanisms in Human Ovarian Cancer Cell Lines Leading to Increased Sensitivity to Cytotoxic Drugs.
    Wojtowicz K; Sterzyńska K; Świerczewska M; Nowicki M; Zabel M; Januchowski R
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTPRK Expression Is Downregulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive CSCs-Like Populations.
    Świerczewska M; Sterzyńska K; Wojtowicz K; Kaźmierczak D; Iżycki D; Nowicki M; Zabel M; Januchowski R
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31027318
    [No Abstract]   [Full Text] [Related]  

  • 9. Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines.
    Januchowski R; Sterzyńska K; Zawierucha P; Ruciński M; Świerczewska M; Partyka M; Bednarek-Rajewska K; Brązert M; Nowicki M; Zabel M; Klejewski A
    Oncotarget; 2017 Jul; 8(30):49944-49958. PubMed ID: 28611294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
    Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
    J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines.
    Klejewski A; Świerczewska M; Zaorska K; Brązert M; Nowicki M; Zabel M; Januchowski R
    Anticancer Res; 2017 Apr; 37(4):1625-1636. PubMed ID: 28373423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of
    Nowacka M; Ginter-Matuszewska B; Świerczewska M; Sterzyńska K; Nowicki M; Januchowski R
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells.
    Tumbarello DA; Temple J; Brenton JD
    Mol Cancer; 2012 May; 11():36. PubMed ID: 22640878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDR gene expression analysis of six drug-resistant ovarian cancer cell lines.
    Januchowski R; Wojtowicz K; Sujka-Kordowska P; Andrzejewska M; Zabel M
    Biomed Res Int; 2013; 2013():241763. PubMed ID: 23484165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines.
    Wojtowicz K; Januchowski R; Nowicki M; Zabel M
    Biomed Pharmacother; 2015 Aug; 74():49-56. PubMed ID: 26349962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The characterization of the sensitive ovarian cancer cell lines A2780 and W1 in response to ovarian CAFs.
    Wojtowicz K; Nowicki M
    Biochem Biophys Res Commun; 2023 Jun; 662():1-7. PubMed ID: 37088000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines.
    Januchowski R; Sterzyńska K; Zaorska K; Sosińska P; Klejewski A; Brązert M; Nowicki M; Zabel M
    J Ovarian Res; 2016 Oct; 9(1):65. PubMed ID: 27756418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
    Cruz-Muñoz W; Di Desidero T; Man S; Xu P; Jaramillo ML; Hashimoto K; Collins C; Banville M; O'Connor-McCourt MD; Kerbel RS
    Angiogenesis; 2014 Jul; 17(3):661-73. PubMed ID: 24569856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells.
    Tumbarello DA; Andrews MR; Brenton JD
    PLoS One; 2016; 11(9):e0162698. PubMed ID: 27622658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
    Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
    Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.